Long-Term Liabilities: The sum of all non-current liabilities.
Lyell Immunopharma, Inc. (LYEL) had Long-Term Liabilities of $46.97M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$0.01M |
|
$-38.85M |
|
-- |
|
$0.01M |
|
$37.27M |
|
$-37.25M |
|
$-1.59M |
|
$-38.85M |
|
$-38.85M |
|
$-38.85M |
|
$-38.85M |
|
$-38.85M |
|
$-38.85M |
|
$-37.25M |
|
$-35.70M |
|
18.27M |
|
18.27M |
|
$-2.13 |
|
$-2.13 |
|
| Balance Sheet Financials | |
$328.20M |
|
$36.72M |
|
$79.76M |
|
$407.96M |
|
$31.88M |
|
-- |
|
|
Long-Term Liabilities |
$46.97M |
$78.84M |
|
$329.12M |
|
$329.12M |
|
$329.12M |
|
19.29M |
|
| Cash Flow Statement Financials | |
$-117.77M |
|
$85.46M |
|
$50.18M |
|
$107.29M |
|
$125.16M |
|
$17.87M |
|
$16.26M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.30 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-248353.30% |
|
-248353.30% |
|
-- |
|
-258973.30% |
|
-258973.30% |
|
$-117.99M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-11.80% |
|
-11.80% |
|
-9.52% |
|
-11.80% |
|
$17.06 |
|
$-6.46 |
|
$-6.45 |
|